의약품 스크리닝용 AI 시장(2025-2029년)

The global AI in drug screening market is forecasted to grow by USD 2983.7 mn during 2024-2029, accelerating at a CAGR of 41.1% during the forecast period. The report on the global AI in drug screening market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising imperative to curtail drug discovery timelines and costs, increasing frequency of cross-industry collaborations and strategic partnerships, continuous advancements in AI technologies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global AI in drug screening market is segmented as below:

By Application

• Drug repurposing
• Target identification
• Lead optimization
• Biomarker discovery

By Type

• Preclinical testing
• Clinical trials
• Toxicity prediction
• Virtual screening

By End-User

• Pharmaceutical companies
• Biotechnology firms
• Research institutes
• Contract research organization

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • The Netherlands
  • Spain
  • Italy
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the proliferation of generative AI in accelerating drug screening as one of the prime reasons driving the global AI in drug screening market growth during the next few years. Also, imperative of explainable AI for regulatory trust and adoption and ai-powered target identification and validation as foundational strategy will lead to sizable demand in the market.

The report on the global AI in drug screening market covers the following areas:

• Global AI in drug screening market sizing
• Global AI in drug screening market forecast
• Global AI in drug screening market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global AI in drug screening market vendors that include Anima Biotech, Atomwise Inc., BenevolentAI, BioXcel Therapeutics Inc., Charles River Laboratories, Deep Genomics Inc., DenovAI, Evotec SE, Exscientia plc, Generate Biomedicines, Iktos, Insilico Medicine, insitro, Isomorphic Labs, Schrodinger Inc., WuXi AppTec Co. Ltd.. Also, the global AI in drug screening market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global AI In Drug Screening Market 2019 - 2023
  • Historic Market Size - Data Table on Global AI In Drug Screening Market 2019 - 2023 ($ million)
• 5.2 Application segment analysis 2019 - 2023
  • Historic Market Size - Application Segment 2019 - 2023 ($ million)
• 5.3 Type segment analysis 2019 - 2023
  • Historic Market Size - Type Segment 2019 - 2023 ($ million)
• 5.4 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Five Forces Analysis

• 6.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 6.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 6.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 6.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 6.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 6.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 6.7 Market condition

7 Market Segmentation by Application

• 7.1 Market segments
• 7.2 Comparison by Application
• 7.3 Drug repurposing - Market size and forecast 2024-2029
• 7.4 Target identification - Market size and forecast 2024-2029
• 7.5 Lead optimization - Market size and forecast 2024-2029
• 7.6 Biomarker discovery - Market size and forecast 2024-2029
• 7.7 Market opportunity by Application
  • Market opportunity by Application ($ million)

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Preclinical testing - Market size and forecast 2024-2029
• 8.4 Clinical trials - Market size and forecast 2024-2029
• 8.5 Toxicity prediction - Market size and forecast 2024-2029
• 8.6 Virtual screening - Market size and forecast 2024-2029
• 8.7 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Pharmaceutical companies - Market size and forecast 2024-2029
• 9.4 Biotechnology firms - Market size and forecast 2024-2029
• 9.5 Research institutes - Market size and forecast 2024-2029
• 9.6 Contract research organization - Market size and forecast 2024-2029
• 9.7 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Customer Landscape

• 10.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Geographic Landscape

• 11.1 Geographic segmentation
• 11.2 Geographic comparison
• 11.3 North America - Market size and forecast 2024-2029
  • 11.3.1 US - Market size and forecast 2024-2029
  • 11.3.2 Canada - Market size and forecast 2024-2029
  • 11.3.3 Mexico - Market size and forecast 2024-2029
• 11.4 Europe - Market size and forecast 2024-2029
  • 11.4.1 Germany - Market size and forecast 2024-2029
  • 11.4.2 UK - Market size and forecast 2024-2029
  • 11.4.3 France - Market size and forecast 2024-2029
  • 11.4.4 The Netherlands - Market size and forecast 2024-2029
  • 11.4.5 Spain - Market size and forecast 2024-2029
  • 11.4.6 Italy - Market size and forecast 2024-2029
  • 11.4.7 Russia - Market size and forecast 2024-2029
• 11.5 Asia - Market size and forecast 2024-2029
  • 11.5.1 China - Market size and forecast 2024-2029
  • 11.5.2 Japan - Market size and forecast 2024-2029
  • 11.5.3 India - Market size and forecast 2024-2029
  • 11.5.4 South Korea - Market size and forecast 2024-2029
  • 11.5.5 Singapore - Market size and forecast 2024-2029
  • 11.5.6 Indonesia - Market size and forecast 2024-2029
  • 11.5.7 Thailand - Market size and forecast 2024-2029
• 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • 11.6.1 Australia - Market size and forecast 2024-2029
  • 11.6.2 Brazil - Market size and forecast 2024-2029
  • 11.6.3 South Africa - Market size and forecast 2024-2029
  • 11.6.4 UAE - Market size and forecast 2024-2029
  • 11.6.5 Saudi Arabia - Market size and forecast 2024-2029
  • 11.6.6 Turkey - Market size and forecast 2024-2029
• 11.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

12 Drivers, Challenges, and Opportunity

• 12.1 Market drivers
  • Rising imperative to curtail drug discovery timelines and costs
  • Increasing frequency of cross-industry collaborations and strategic partnerships
  • Continuous advancements in AI technologies
• 12.2 Market challenges
  • Data accessibility, quality, and sharing
  • High cost and resource intensiveness of AI implementation
  • Evolving regulatory landscape and model validation
• 12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 12.4 Market opportunities
  • Proliferation of generative AI in accelerating drug screening
  • Imperative of explainable AI for regulatory trust and adoption
  • AI-powered target identification and validation as foundational strategy

13 Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 13.3 Landscape disruption
  • Overview on factors of disruption
• 13.4 Industry risks
  • Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered
• 14.2 Company ranking index
  • Company ranking index
• 14.3 Market positioning of companies
  • Matrix on companies position and classification
• 14.4 Anima Biotech
  • Anima Biotech - Overview
  • Anima Biotech - Product / Service
  • Anima Biotech - Key offerings
  • SWOT
• 14.5 Atomwise Inc.
  • Atomwise Inc. - Overview
  • Atomwise Inc. - Product / Service
  • Atomwise Inc. - Key offerings
  • SWOT
• 14.6 BenevolentAI
  • BenevolentAI - Overview
  • BenevolentAI - Product / Service
  • BenevolentAI - Key offerings
  • SWOT
• 14.7 BioXcel Therapeutics Inc.
  • BioXcel Therapeutics Inc. - Overview
  • BioXcel Therapeutics Inc. - Product / Service
  • BioXcel Therapeutics Inc. - Key offerings
  • SWOT
• 14.8 Charles River Laboratories
  • Charles River Laboratories - Overview
  • Charles River Laboratories - Business segments
  • Charles River Laboratories - Key offerings
  • Charles River Laboratories - Segment focus
  • SWOT
• 14.9 Deep Genomics Inc.
  • Deep Genomics Inc. - Overview
  • Deep Genomics Inc. - Product / Service
  • Deep Genomics Inc. - Key offerings
  • SWOT
• 14.10 Evotec SE
  • Evotec SE - Overview
  • Evotec SE - Business segments
  • Evotec SE - Key news
  • Evotec SE - Key offerings
  • Evotec SE - Segment focus
  • SWOT
• 14.11 Exscientia plc
  • Exscientia plc - Overview
  • Exscientia plc - Product / Service
  • Exscientia plc - Key offerings
  • SWOT
• 14.12 Generate Biomedicines
  • Generate Biomedicines - Overview
  • Generate Biomedicines - Product / Service
  • Generate Biomedicines - Key offerings
  • SWOT
• 14.13 Iktos
  • Iktos - Overview
  • Iktos - Product / Service
  • Iktos - Key offerings
  • SWOT
• 14.14 Insilico Medicine
  • Insilico Medicine - Overview
  • Insilico Medicine - Product / Service
  • Insilico Medicine - Key offerings
  • SWOT
• 14.15 insitro
  • insitro - Overview
  • insitro - Product / Service
  • insitro - Key offerings
  • SWOT
• 14.16 Isomorphic Labs
  • Isomorphic Labs - Overview
  • Isomorphic Labs - Product / Service
  • Isomorphic Labs - Key offerings
  • SWOT
• 14.17 Schrodinger Inc.
  • Schrodinger Inc. - Overview
  • Schrodinger Inc. - Business segments
  • Schrodinger Inc. - Key offerings
  • Schrodinger Inc. - Segment focus
  • SWOT
• 14.18 WuXi AppTec Co. Ltd.
  • WuXi AppTec Co. Ltd. - Overview
  • WuXi AppTec Co. Ltd. - Business segments
  • WuXi AppTec Co. Ltd. - Key offerings
  • WuXi AppTec Co. Ltd. - Segment focus
  • SWOT

15 Appendix

• 15.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 15.4 Research methodology
  • Research methodology
• 15.5 Data procurement
  • Information sources
• 15.6 Data validation
  • Data validation
• 15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 15.8 Data synthesis
  • Data synthesis
• 15.9 360 degree market analysis
  • 360 degree market analysis
• 15.10 List of abbreviations
  • List of abbreviations